{
  "study_id": "NCT01377376",
  "study_title": "A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)",
  "table_name": "Table 1",
  "table_title": "Demographic and baseline characteristics in the intent-to-treat population",
  "footnotes": [
    "Advanced or recurrent; a subject with a history of curative surgeries is defined as 'recurrent' and those without are defined as 'advanced'.",
    "ECOG PS, Eastern Cooperative Oncology Group Performance Status."
  ],
  "groups": [
    {
      "name": "Placebo group",
      "n": 153,
      "type": "control"
    },
    {
      "name": "Tivantinib group",
      "n": 154,
      "type": "intervention"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age (years)",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "Age (years)"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "Age (years)"
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age (years)",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "numeric_single",
          "value": 63.0,
          "raw_string": "63.0"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "numeric_single",
          "value": 63.0,
          "raw_string": "63.0"
        }
      ]
    },
    {
      "original_label": "Range",
      "standardized_name": "Age Range",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age (years)",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "numeric_mean_range",
          "range_min": 27.0,
          "range_max": 84.0,
          "raw_string": "27-84"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "numeric_mean_range",
          "range_min": 33.0,
          "range_max": 83.0,
          "raw_string": "33-83"
        }
      ]
    },
    {
      "original_label": "Gender",
      "standardized_name": "Sex",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "Gender"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "Gender"
        }
      ]
    },
    {
      "original_label": "Male",
      "standardized_name": "Sex",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Gender",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 102.0,
          "percentage": 66.7,
          "raw_string": "102 66.7"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 109.0,
          "percentage": 70.8,
          "raw_string": "109 70.8"
        }
      ]
    },
    {
      "original_label": "Female",
      "standardized_name": "Sex",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Gender",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 33.3,
          "raw_string": "51 33.3"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 45.0,
          "percentage": 29.2,
          "raw_string": "45 29.2"
        }
      ]
    },
    {
      "original_label": "Country",
      "standardized_name": "Country",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "Country"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "Country"
        }
      ]
    },
    {
      "original_label": "Japan",
      "standardized_name": "Country",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Country",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 118.0,
          "percentage": 77.1,
          "raw_string": "118 77.1"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 115.0,
          "percentage": 74.7,
          "raw_string": "115 74.7"
        }
      ]
    },
    {
      "original_label": "Korea",
      "standardized_name": "Country",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Country",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 18.3,
          "raw_string": "28 18.3"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 18.8,
          "raw_string": "29 18.8"
        }
      ]
    },
    {
      "original_label": "Taiwan",
      "standardized_name": "Country",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Country",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 4.6,
          "raw_string": "7 4.6"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 6.5,
          "raw_string": "10 6.5"
        }
      ]
    },
    {
      "original_label": "CYP2C19",
      "standardized_name": "CYP2C19 Phenotype",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "CYP2C19"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "CYP2C19"
        }
      ]
    },
    {
      "original_label": "Extensive metabolizer",
      "standardized_name": "CYP2C19 Phenotype",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "CYP2C19",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 125.0,
          "percentage": 81.7,
          "raw_string": "125 81.7"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 126.0,
          "percentage": 81.8,
          "raw_string": "126 81.8"
        }
      ]
    },
    {
      "original_label": "Poor metabolizer",
      "standardized_name": "CYP2C19 Phenotype",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "CYP2C19",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 18.3,
          "raw_string": "28 18.3"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 18.2,
          "raw_string": "28 18.2"
        }
      ]
    },
    {
      "original_label": "Number of prior therapies",
      "standardized_name": "Number of Prior Therapies",
      "category": "Clinical History",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "Number of prior therapies"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "Number of prior therapies"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "Number of Prior Therapies",
      "category": "Clinical History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of prior therapies",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 90.0,
          "percentage": 58.8,
          "raw_string": "90 58.8"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 92.0,
          "percentage": 59.7,
          "raw_string": "92 59.7"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "Number of Prior Therapies",
      "category": "Clinical History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of prior therapies",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 63.0,
          "percentage": 41.2,
          "raw_string": "63 41.2"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 62.0,
          "percentage": 40.3,
          "raw_string": "62 40.3"
        }
      ]
    },
    {
      "original_label": "ECOG PS at screening",
      "standardized_name": "ECOG Performance Status",
      "category": "Baseline Clinical Assessment",
      "time_point": "Screening",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "ECOG PS at screening"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "ECOG PS at screening"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status",
      "category": "Baseline Clinical Assessment",
      "time_point": "Screening",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS at screening",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 33.3,
          "raw_string": "51 33.3"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 42.9,
          "raw_string": "66 42.9"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status",
      "category": "Baseline Clinical Assessment",
      "time_point": "Screening",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS at screening",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 102.0,
          "percentage": 66.7,
          "raw_string": "102 66.7"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 88.0,
          "percentage": 57.1,
          "raw_string": "88 57.1"
        }
      ]
    },
    {
      "original_label": "Disease status at randomization",
      "standardized_name": "Disease Status at Randomization",
      "category": "Disease Characteristics",
      "time_point": "Randomization",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "Disease status at randomizationa"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "Disease status at randomizationa"
        }
      ]
    },
    {
      "original_label": "Advanced",
      "standardized_name": "Disease Status at Randomization",
      "category": "Disease Characteristics",
      "time_point": "Randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease status at randomization",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 122.0,
          "percentage": 79.7,
          "raw_string": "122 79.7"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 123.0,
          "percentage": 79.9,
          "raw_string": "123 79.9"
        }
      ]
    },
    {
      "original_label": "Recurrent",
      "standardized_name": "Disease Status at Randomization",
      "category": "Disease Characteristics",
      "time_point": "Randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease status at randomization",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 20.3,
          "raw_string": "31 20.3"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 20.1,
          "raw_string": "31 20.1"
        }
      ]
    },
    {
      "original_label": "Smoking history",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "Smoking history"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "Smoking history"
        }
      ]
    },
    {
      "original_label": "Current",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking history",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.3,
          "raw_string": "5 3.3"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 7.8,
          "raw_string": "12 7.8"
        }
      ]
    },
    {
      "original_label": "Previous",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking history",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 109.0,
          "percentage": 71.2,
          "raw_string": "109 71.2"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 101.0,
          "percentage": 65.6,
          "raw_string": "101 65.6"
        }
      ]
    },
    {
      "original_label": "Never",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking history",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 39.0,
          "percentage": 25.5,
          "raw_string": "39 25.5"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 41.0,
          "percentage": 26.6,
          "raw_string": "41 26.6"
        }
      ]
    },
    {
      "original_label": "Tumor stage at randomization",
      "standardized_name": "Tumor Stage at Randomization",
      "category": "Disease Characteristics",
      "time_point": "Randomization",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "Tumor stage at randomization"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "Tumor stage at randomization"
        }
      ]
    },
    {
      "original_label": "IIIa",
      "standardized_name": "Tumor Stage at Randomization",
      "category": "Disease Characteristics",
      "time_point": "Randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage at randomization",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.7,
          "raw_string": "1 0.7"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 0"
        }
      ]
    },
    {
      "original_label": "IIIb",
      "standardized_name": "Tumor Stage at Randomization",
      "category": "Disease Characteristics",
      "time_point": "Randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage at randomization",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 5.9,
          "raw_string": "9 5.9"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 3.9,
          "raw_string": "6 3.9"
        }
      ]
    },
    {
      "original_label": "IV",
      "standardized_name": "Tumor Stage at Randomization",
      "category": "Disease Characteristics",
      "time_point": "Randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage at randomization",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 143.0,
          "percentage": 93.5,
          "raw_string": "143 93.5"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 148.0,
          "percentage": 96.1,
          "raw_string": "148 96.1"
        }
      ]
    },
    {
      "original_label": "c-Met expression (IHC)",
      "standardized_name": "c-Met Expression (IHC)",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "c-Met expression (IHC)"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "c-Met expression (IHC)"
        }
      ]
    },
    {
      "original_label": "High",
      "standardized_name": "c-Met Expression (IHC)",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "c-Met expression (IHC)",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 77.0,
          "percentage": 50.3,
          "raw_string": "77 50.3"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 83.0,
          "percentage": 53.9,
          "raw_string": "83 53.9"
        }
      ]
    },
    {
      "original_label": "Low",
      "standardized_name": "c-Met Expression (IHC)",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "c-Met expression (IHC)",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 69.0,
          "percentage": 45.1,
          "raw_string": "69 45.1"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 65.0,
          "percentage": 42.2,
          "raw_string": "65 42.2"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "c-Met Expression (IHC)",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "c-Met expression (IHC)",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 4.6,
          "raw_string": "7 4.6"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 3.9,
          "raw_string": "6 3.9"
        }
      ]
    },
    {
      "original_label": "c-Met gene copy",
      "standardized_name": "c-Met Gene Copy Number",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "header",
          "raw_string": "c-Met gene copy"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "header",
          "raw_string": "c-Met gene copy"
        }
      ]
    },
    {
      "original_label": "Amplification",
      "standardized_name": "c-Met Gene Copy Number",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "c-Met gene copy",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 6.5,
          "raw_string": "10 6.5"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 3.9,
          "raw_string": "6 3.9"
        }
      ]
    },
    {
      "original_label": "Normal",
      "standardized_name": "c-Met Gene Copy Number",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "c-Met gene copy",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 37.0,
          "percentage": 24.2,
          "raw_string": "37 24.2"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 47.0,
          "percentage": 30.5,
          "raw_string": "47 30.5"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "c-Met Gene Copy Number",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "c-Met gene copy",
      "group_data": [
        {
          "group_name": "Placebo group",
          "data_type": "categorical_count_percentage",
          "count": 106.0,
          "percentage": 69.3,
          "raw_string": "106 69.3"
        },
        {
          "group_name": "Tivantinib group",
          "data_type": "categorical_count_percentage",
          "count": 101.0,
          "percentage": 65.6,
          "raw_string": "101 65.6"
        }
      ]
    }
  ]
}